Furthermore, since JAK1 is associated with multiple cytokine receptors and STATs (Fig. 2) and since tofacitinib also inhibits JAK2 to some extent, its activity against IBD is difficult to understand according to the current knowledge of JAK inhibitors. The gene discussed is JAK1; the disease is inflammatory bowel disease.